189 related articles for article (PubMed ID: 37085901)
1. Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia.
Rutten MGS; Lei Y; Hoogerland JH; Bloks VW; Yang H; Bos T; Krishnamurthy KA; Bleeker A; Koster MH; Thomas RE; Wolters JC; van den Bos H; Mithieux G; Rajas F; Mardinoglu A; Spierings DCJ; de Bruin A; van de Sluis B; Oosterveer MH
Cancer Metab; 2023 Apr; 11(1):5. PubMed ID: 37085901
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
[TBL] [Abstract][Full Text] [Related]
3. Hepatic ChREBP orchestrates intrahepatic carbohydrate metabolism to limit hepatic glucose 6-phosphate and glycogen accumulation in a mouse model for acute Glycogen Storage Disease type Ib.
Krishnamurthy KA; Rutten MGS; Hoogerland JA; van Dijk TH; Bos T; Koehorst M; de Vries MP; Kloosterhuis NJ; Havinga H; Schomakers BV; van Weeghel M; Wolters JC; Bakker BM; Oosterveer MH
Mol Metab; 2024 Jan; 79():101838. PubMed ID: 37995884
[TBL] [Abstract][Full Text] [Related]
4. Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing.
Rutten MGS; Derks TGJ; Huijkman NCA; Bos T; Kloosterhuis NJ; van de Kolk KCWA; Wolters JC; Koster MH; Bongiovanni L; Thomas RE; de Bruin A; van de Sluis B; Oosterveer MH
Hepatology; 2021 Nov; 74(5):2491-2507. PubMed ID: 34157136
[TBL] [Abstract][Full Text] [Related]
5. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM
Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282
[No Abstract] [Full Text] [Related]
6. The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice.
Rajas F; Dentin R; Cannella Miliano A; Silva M; Raffin M; Levavasseur F; Gautier-Stein A; Postic C; Mithieux G
Mol Metab; 2021 Jan; 43():101108. PubMed ID: 33137488
[TBL] [Abstract][Full Text] [Related]
7. Yap signalling regulates ductular reactions in mice with CRISPR/Cas9-induced glycogen storage disease type Ia.
Xie Y; Hu B; Gao Y; Tang Y; Chen G; Shen J; Jiang Z; Jiang H; Han J; Yan J; Jin L
Anim Cells Syst (Seoul); 2022; 26(6):300-309. PubMed ID: 36605584
[TBL] [Abstract][Full Text] [Related]
8. Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor α (LXRα) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1.
Grefhorst A; Schreurs M; Oosterveer MH; Cortés VA; Havinga R; Herling AW; Reijngoud DJ; Groen AK; Kuipers F
Biochem J; 2010 Dec; 432(2):249-54. PubMed ID: 20854262
[TBL] [Abstract][Full Text] [Related]
9. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
Cho JH; Weinstein DA; Lee YM
J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
[TBL] [Abstract][Full Text] [Related]
10. Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.
Waskowicz LR; Zhou J; Landau DJ; Brooks ED; Lim A; Yavarow ZA; Kudo T; Zhang H; Wu Y; Grant S; Young SP; Huat BB; Yen PM; Koeberl DD
Hum Mol Genet; 2019 Jan; 28(1):143-154. PubMed ID: 30256948
[TBL] [Abstract][Full Text] [Related]
11. Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels.
Saeed A; Hoogerland JA; Wessel H; Heegsma J; Derks TGJ; van der Veer E; Mithieux G; Rajas F; Oosterveer MH; Faber KN
Hum Mol Genet; 2020 Jan; 29(2):264-273. PubMed ID: 31813960
[TBL] [Abstract][Full Text] [Related]
12. Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia.
Hijmans BS; Boss A; van Dijk TH; Soty M; Wolters H; Mutel E; Groen AK; Derks TGJ; Mithieux G; Heerschap A; Reijngoud DJ; Rajas F; Oosterveer MH
Hepatology; 2017 Dec; 66(6):2042-2054. PubMed ID: 28727166
[TBL] [Abstract][Full Text] [Related]
13. Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.
Yavarow ZA; Kang HR; Waskowicz LR; Bay BH; Young SP; Yen PM; Koeberl DD
Hum Mol Genet; 2020 Jan; 29(2):286-294. PubMed ID: 31816064
[TBL] [Abstract][Full Text] [Related]
14. Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia.
Hoogerland JA; Peeks F; Hijmans BS; Wolters JC; Kooijman S; Bos T; Bleeker A; van Dijk TH; Wolters H; Gerding A; van Eunen K; Havinga R; Pronk ACM; Rensen PCN; Mithieux G; Rajas F; Kuipers F; Reijngoud DJ; Derks TGJ; Oosterveer MH
J Inherit Metab Dis; 2021 Jul; 44(4):879-892. PubMed ID: 33739445
[TBL] [Abstract][Full Text] [Related]
15. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia.
La Rose AM; Bazioti V; Hoogerland JA; Svendsen AF; Groenen AG; van Faassen M; Rutten MGS; Kloosterhuis NJ; Dethmers-Ausema B; Nijland JH; Mithieux G; Rajas F; Kuipers F; Lukens MV; Soehnlein O; Oosterveer MH; Westerterp M
Mol Metab; 2021 Nov; 53():101265. PubMed ID: 34091064
[TBL] [Abstract][Full Text] [Related]
17. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis and clinical investigations of medically diagnosed GSD 1a patients from Pakistan.
Gul B; Firasat S; Shan T; Tehreem R; Afshan K
PLoS One; 2023; 18(11):e0288965. PubMed ID: 38033126
[TBL] [Abstract][Full Text] [Related]
19. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy.
Yiu WH; Lee YM; Peng WT; Pan CJ; Mead PA; Mansfield BC; Chou JY
Mol Ther; 2010 Jun; 18(6):1076-84. PubMed ID: 20389290
[TBL] [Abstract][Full Text] [Related]
20. Minimal hepatic glucose-6-phosphatase-α activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia.
Lee YM; Kim GY; Pan CJ; Mansfield BC; Chou JY
Mol Genet Metab Rep; 2015 Jun; 3():28-32. PubMed ID: 26937391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
